Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

BG-12 demonstrated efficacy in patients with RRMS by decreasing new Gd+ lesion development across a range of subgroups defined by baseline disease characteristics or demographics.